Home
overview
Cardiovascular drugs have maintained their place as the dominant therapeutic segment of the pharmaceutical market over the last 2 decades and this is a trend that is certainly set to continue. However, today it seems that real progress in terms of R & D seems to have slowed down in this fiercely competitive market, with a number of ‘me too’ drugs but little in the way of innovative new products.

This conference will provide the platform you need to find out what is really happening in the Cardiovascular market, how the competitve dynamics are changing and where the future opportunities lie. What are the lead players up to and in which directions do they see the industry going? What do they consider has been the key to their success? And where should the industry be investing?

The event aims to identify key innovations in the search for new therapies, with a focus on new drugs in development for cardiac diseases, including heart failure, arrhythmia, athersclerosis and coronary artery disease. It will also look at the future of gene and stem cell therapies.

This event is designed for people involved in all aspects of Cardiovascular drug development, product management, marketing and business development. It will provide an opportunity for leading experts to discuss the current obstacles and how they might be overcome, to identify growth areas for the industry, establish contacts and to learn from the experience of others.

A unique opportunity to learn from leading industry experts including:
· Prof Andreas Busch, Vice President & Head, DG Cardiovascular Disease, Aventis
· Dr Francis Plat, Executive Director, Novartis
· Dr Chris Vlahos, Head, Atherosclerosis Vascular Wall Drug Discovery Team, Eli Lilly
· Dr Randolph Seidler, Senior Principle Scientist, Boehringer Ingelheim
· Dr Paul Burton, Associate Director, Clinical Development, Amgen
· Dr Madhu Chintala, Section Leader, Cardiovascular & Ancillary Pharmacology, Schering Plough
· Dr Lewis Schwartz, Global Medical Director, Thrombosis, Abbott
· Dr Matthew Pollman, Director, Cardiovascular Biology & Personalized Medicine, Millennium
· Dr Luiz Belardinelli, Vice President, Drug Research & Pharmacology, CV Therapeutics
· Dr Stuart Young, Head, Medical & Regulatory Affairs, Valentis
· Dr Jack Reich, Founder, Formerly Chairman & Chief Executive Officer, Collateral Therapeutics

Key benefits of attending:
GLOBAL MARKET ANALYSIS: Hear about leading products and categories with the cardiac field
PREVENTION & TREATMENT OF ATHEROSCLEROSIS: Evaluate successes and failures associated with atherosclerosis treatments
ARRHYTHMIA STRATEGIES: Gain an insight into present and future developments
OXIPUTINOL FOR CONGESTIVE HEART FAILURE: A case study on how to improve cardiac efficiency
GENE THERAPY FOR CORONARY ARTERY DISEASE: Learn about the background and medical needs for coronary artery disease
INDUSTRY LEADERS: Network and discuss ideas with the leaders in the field

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Matthew Pollman

Dr Matthew Pollman, Director, Cardiovascular Biology & Personalized Medicine, Millennium

9:10 GLOBAL MARKET ANALYSIS

Dr Nicola Maidwell

Dr Nicola Maidwell, Analyst, Decision Resources I

  • Key clinical trials for cardiac drugs
  • Emerging products
  • Expanding markets
  • Shrinking markets
  • Future outlook
  • 9:40 PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

    Dr Paul Burton

    Dr Paul Burton, Associate Director, Clinical Development, Amgen

  • Successes and failures associated with atherosclerosis treatments
  • What are the exciting areas in the field?
  • Development problems
  • Clinical trial design
  • Future prospects
  • 10:20 THERAPEUTIC REGULATION OF ANGIOGENESIS WITH ENGINEERED TRANSCRIPTION

    Dr Tyler Martin

    Dr Tyler Martin, Vice President, Development, Sangamo Biosciences

  • Zing finger DNA binding protein transcription factors (ZFP TFs) a new class of therapeutics for the treatment of human diseases
  • Vascular endothelial growth factor A (VEGF-A)
  • Alternate splicing of the endogenous (VEG-A)
  • Successful targeting ZFP TFs to the human endogenous VEGF-A locus
  • Induction of blood vessel growth in mouse and rabbit models
  • Evaluating new ZFP TFs targeted to endogenous ANG-1 (angiopoietin-1) and PLN (phospholamban) loci
  • 11:00 Morning Coffee

    11:20 CONGESTIVE HEART FAILURE

    Dr Chris Vlahos

    Dr Chris Vlahos, Head, Atherosclerosis Vascular Wall Drug Discovery Team, Eli Lilly

  • Current state of the market
  • Novel targets and approaches
  • Technological advances
  • Future developments
  • 12:00 CASE STUDY: OXIPURINOL FOR CHF

    Dr Alan Moore

    Dr Alan Moore, Executive Vice President, Clinical Development & Regulatory Affairs, Cardiome

  • A new role for xanthine oxidase inhibitors
  • Pre-clinical evidence
  • Clinical experience in CHF
  • Ongoing phase ll/lll clinical trials
  • 12:40 Networking Lunch

    14:00 GENETIC THERAPY FOR VASCULAR PROLIFERATIVE DISORDERS

    Dr Lewis Schwartz

    Dr Lewis Schwartz, Global Medical Director, Thrombosis, Abbott

  • Etiology and impact
  • Case studies in vein and percutaneous angioplasty
  • Traditional pharmacological approach
  • Gene therapy – vectors and beyond
  • Clinical application of genetic therapy
  • 14:40 CARDIAC DISEASE IN SILICO

    Prof Denis Noble

    Prof Denis Noble, Professor, Cardiovascular Physiology, University of Oxford

  • The heart in silico
  • Genetic factors
  • Drugs and drug-gene interactions
  • Understanding cardiac ischaemia
  • 15:20 Afternoon Tea

    15:40 CARDIAC DISEASE RESEARCH IN VIVO

    Anthony Chan

    Anthony Chan, Associate Director, Medical Solutions, Cardiovascular Therapeutics, Europe, Quintiles

  • Global cardiac disease burden
  • R&D pipelines in cardiovascular research
  • Globalisation of cardiovascular research
  • Recruitment challenges
  • Traditional countries
  • Expanding countries: CEE
    Emerging countries: SA, LA, India
  • 16:20 NITRIC OXIDE AS CARDIOVASCULAR THERAPY

    Dr Eduardo Salas

    Dr Eduardo Salas, Research & Development Director, Lácer

  • Nitric oxide in cardiovascular physiology and pathology
  • Nitric oxide donors in the market
  • Innovative new nitric oxide donors for the treatment of chronic stable angina
  • Innovative new nitric oxide donors for the treatment of thrombosis
  • 17:00 Chairman’s Closing Remarks and Close of Day

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Denis Noble

    Prof Denis Noble, Professor, Cardiovascular Physiology, University of Oxford

    9:10 ARRHYTHMIA STRATEGIES

    Dr Andreas Busch

    Dr Andreas Busch, Vice President & Head, DG Cardiovascular Disease, Aventis

  • Downturn in the market
  • Clinical failure
  • Strategies for successful generation of new lead structures and clinical candidates
  • How to generate rapidly high quality leads for ion channels
  • Aventis’ strategy for the discovery and development of anti-arrhythmics for atrial and ventricular arrhythmia
  • Aventis’ findings for clinical candidates in atrial and ventricular arrhythmia
  • 9:40 CASE STUDY: RSD1235

    Dr Gregory Beatch

    Dr Gregory Beatch, Vice President, External Scientific Affairs, Cardiome

  • Atrial selectivity: the key to safety
  • Molecular and substrate targeting: keys to efficacy
  • Pre-clinical studies
  • Clinical safety and efficacy results
  • Ongoing phase lll clinical trials
  • 10:20 MARKERS OF PROARRHYTHMIC RISK ASSOCIATED WITH QT-PROLONGING DRUGS

    Dr Luiz Belardinelli

    Dr Luiz Belardinelli, Vice President, Drug Research & Pharmacology, CV Therapeutics

  • How to assess the risk of proarrhythmia by QT-prolonging drugs
  • The electrophysiological basis of ventricular repolarization
  • Mechanism of Torsade de Pointes
  • The role of early after-depolarizations
  • The role of increased spatial dispersion of ventricular repolarization
  • Predisposing factors for drug-induced Torsade de Pointes
  • 11:00 Morning Coffee

    11:20 GENE THERAPY FOR CORONARY ARTERY DISEASE

    Dr Jack Reich

    Dr Jack Reich, Founder, Formerly Chairman & Chief Executive Officer, Collateral Therapeutics

  • Coronary disease – background and medical need
  • Delivery of an angiogenic gene to affect the transfer of genetic information into the heart cells
  • Methods of gene therapy
  • Effectiveness in comparison to surgery and drugs
  • Regulatory approaches
  • Is gene therapy a reality?
  • 12:00 THROMBIN RECEPTOR ANTAGONISTS AS A NOVEL APPROACH TO PREVENTING THROMBOSIS

    Dr Madhu Chintala

    Dr Madhu Chintala, Section Leader, Cardiovascular & Ancillary Pharmacology, Schering Plough

  • Current approaches to treating arterial thrombosis and their limitations
  • Thrombin receptor antagonist: novel class of antiplatelet agents
  • Selective inhibitor of the antiplatelet actions of thrombin
  • Insights from pre-clinical studies in preventing thrombosis
  • 12:40 Networking Lunch

    14:00 DEVELOPMENTALLY REGULATED ENDOTHELIAL CELL LOCUS #1 (DEL-1) ANGIOGENIC GENE FOR THE TREATMENT OF ATHEROGENIC, ISCHENIC DISEASES

    Dr Stuart Young

    Dr Stuart Young, Head, Medical & Regulatory Affairs, Valentis

  • GenePlasmid containing Del-1 (VLTS-589) delivered with a polymer
  • Pre-clinical studies demonstrate new capillary and arteriole formation and improvements in exercise tolerance with no associated toxicity
  • Subjects (20 in 6 cohorts - enrollment is on-going in cohort 6), received intramuscular injections ranging from 3 to 84 mg administered to 1 lower extremity. There were no serious adverse events attributable to VTLS-589
  • Ecchymosis at the injection sites, noted in 3 subjects, was thought to be due to the needle puncture procedure
  • Modest cohort-related improvements were seen in rest pain, neurosensory deficit and palpated pulses. Improvements in claudication stage (#improved#in cohort) were observed: 1/5, 0/3, 1/3, 3/3, 3/3, 3/3, (C 1 to 6 respectively). Improvements were also observed in exercise treadmill time (ETT) and ankle/brachial index (ABI)
  • Conclusion: VLTS-589 appears to be safe in humans and may be useful in managing patients with PAD
  • 14:40 REDOX-BASED MULTIFUNCTIONAL THERAPEUTICS

    Dr Stephen Flaim

    Dr Stephen Flaim, Senior Vice President, Research & Development, Galileo Pharmaceuticals

  • Role of inflammation in myocardial ischaemia and CHF
  • Need for multifunctional therapeutics
  • Identification of promising compounds
  • GLI-5021 in MI and CHF
  • Next steps
  • 15:20 Afternoon Tea

    15:40 ISCHAEMIA-REPERFUSION INJURY

    Dr Randolph Seidler

    Dr Randolph Seidler, Senior Principle Scientist, Boehringer Ingelheim

  • Unmet clinical need and market
  • Drug development and to generate efficacious and safe development compounds
  • Experimental strategies and translation of preclinical experiments into clinical benefit
  • Recent clinical experience and outlook
  • 16:20 POST MYOCARDIAL INFARCTION

    Dr Francis Plat

    Dr Francis Plat, Executive Director, Novartis

  • Objectives of treatment
  • New studies
  • New paradigm
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.